Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phoebe Rich

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Dermatology Practical & Conceptual|June 1, 2022
Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H TrialKristian Reich, Lars Erik Kristensen, Saxon D Smith, et al.
Journal of the American Academy of Dermatology|December 18, 2007
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 yearPhoebe Rich, Christopher E M Griffiths, Kristian Reich, et al.
Journal of the American Academy of Dermatology|May 10, 2015
Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studiesBoni E Elewski, Raza Aly, Sheryl L Baldwin, et al.
Journal of the American Academy of Dermatology|November 27, 2012
Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studiesBoni E Elewski, Phoebe Rich, Richard Pollak, et al.
The Journal of Dermatological Treatment|April 26, 2021
Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE studyBardur Sigurgeirsson, Knut Schäkel, Chih-Ho Hong, et al.
The New England Journal of Medicine|February 7, 2024
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque PsoriasisRobert Bissonnette, Andreas Pinter, Laura K Ferris, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|August 16, 2021
Expert Consensus on Nail Procedures and Selection of CPT CodesJulia O Baltz, Adam Rubin, Chris Adigun, et al.
Journal of the American Academy of Dermatology|December 20, 2023
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasisAndrew Blauvelt, Phoebe Rich, Howard Sofen, et al.
Cutis|August 2, 2003
Efficacy and safety of a new triple-combination agent for the treatment of facial melasmaSusan C Taylor, Helen Torok, Terry Jones, et al.
Dermatology and Therapy|October 26, 2025
Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16Eingun James Song, Benjamin Ehst, Brad Glick, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Dermatology Practical & Conceptual|June 1, 2022
Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H TrialKristian Reich, Lars Erik Kristensen, Saxon D Smith, et al.
Journal of the American Academy of Dermatology|December 18, 2007
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 yearPhoebe Rich, Christopher E M Griffiths, Kristian Reich, et al.
Journal of the American Academy of Dermatology|May 10, 2015
Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studiesBoni E Elewski, Raza Aly, Sheryl L Baldwin, et al.
Journal of the American Academy of Dermatology|November 27, 2012
Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studiesBoni E Elewski, Phoebe Rich, Richard Pollak, et al.
The Journal of Dermatological Treatment|April 26, 2021
Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE studyBardur Sigurgeirsson, Knut Schäkel, Chih-Ho Hong, et al.
The New England Journal of Medicine|February 7, 2024
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque PsoriasisRobert Bissonnette, Andreas Pinter, Laura K Ferris, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|August 16, 2021
Expert Consensus on Nail Procedures and Selection of CPT CodesJulia O Baltz, Adam Rubin, Chris Adigun, et al.
Journal of the American Academy of Dermatology|December 20, 2023
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasisAndrew Blauvelt, Phoebe Rich, Howard Sofen, et al.
Cutis|August 2, 2003
Efficacy and safety of a new triple-combination agent for the treatment of facial melasmaSusan C Taylor, Helen Torok, Terry Jones, et al.
Dermatology and Therapy|October 26, 2025
Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16Eingun James Song, Benjamin Ehst, Brad Glick, et al.
Pageof 9